

# Correspondence on COVID-19 Vaccination and Acquired Haemophilia A

Clinical and Applied Thrombosis/Hemostasis  
Volume 28: 1-1  
© The Author(s) 2022  
Article reuse guidelines:  
[sagepub.com/journals-permissions](https://sagepub.com/journals-permissions)  
DOI: [10.1177/10760296221100808](https://doi.org/10.1177/10760296221100808)  
[journals.sagepub.com/home/cat](https://journals.sagepub.com/home/cat)  


Pathum Sookaromdee<sup>1</sup>  and Viroj Wiwanitkit<sup>2,3</sup>

Date received: 5 April 2022; accepted: 25 April 2022.

Dear Editor, we would like to correspond and share ideas on the publication “Haemostatic Disarray Following COVID-19 Vaccine - a Case of Acquired Haemophilia A (AHA).”<sup>1</sup> A case of AHA was described by O’Shea et al one week after receiving the Pfizer-BioNTech SARS-CoV-2 vaccination.<sup>1</sup> “O’Shea et al examined the immunopathogenesis of AHA caused by the COVID-19 vaccination.”<sup>1</sup> We agree that the patient had AHA after receiving COVID-19 vaccine. It is important to remember, however, that not all clinical problems in vaccine recipients are caused by immunization. Other probable causes of AHA should be considered in this circumstance. The underlying illnesses in this patient were prostate cancer and non-insulin dependent diabetes. There has been a link between these two disorders and AHA.<sup>2,3</sup> The present patient was given rituximab and steroid. Six weeks following diagnosis, his Factor VIII level was normal and his inhibitor screen was negative. Rituximab is also an adjuvant therapy that has been shown to be helpful in the treatment of prostate cancer.<sup>4</sup> When it is applied, it might have anti-tumor effect on the prostate cancer. In addition to the abnormal immune induced by COVID-19 vaccine, it’s possible that the AHA in this situation is caused by the cancer.

## Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

## Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

## ORCID iD

Pathum Sookaromdee  <https://orcid.org/0000-0002-8859-5322>

## References

1. O’Shea E, Daly O, Duggan C, Crowley M. Haemostatic disarray following COVID-19 vaccine - a case of acquired haemophilia A. *Clin Appl Thromb Hemost.* 2022;28:10760296221077981.
2. Bello CT, Vasylenko Y, Esteves J, Vasconcelos CA. Diabetes mellitus and acquired haemophilia: new association? *BMJ Case Rep.* 2017; 2017: bcr2017219807. doi:10.1136/bcr-2017-219807
3. Olivares-Hernández A, Figuero-Pérez L, Fonseca-Sánchez E acquired haemophilia A secondary to metastatic prostate cancer. *Med Clin (Barc).* 2022;S0025-7753(22):00039-2.
4. Ryan ST, Zhang J, Burner DN, et al. Neoadjuvant rituximab modulates the tumor immune environment in patients with high risk prostate cancer. *J Transl Med.* 2020;18(1):214. doi:10.1186/s12967-020-02370-4

<sup>1</sup>Private Academic Consultant, Bangkok Thailand

<sup>2</sup>Joseph Ayobabalola University, Ikeji- Arakeji, Nigeria

<sup>3</sup>Dr DY Patil University, Pune, India

## Corresponding Author:

Pathum Sookaromdee, Private Academic Consultant, Bangkok Thailand.  
Email: pathumsook@gmail.com



Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (<https://creativecommons.org/licenses/by-nc/4.0/>) which permits non-commercial use,

reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (<https://us.sagepub.com/en-us/nam/open-access-at-sage>).